无糖尿病患者使用胰高血糖素样肽1受体激动剂后的青光眼风险
该回顾性队列研究基于TriNetX国际电子健康记录(2004年1月至2024年12月),比较无糖尿病的超重或肥胖患者使用GLP-1RA与替代减重药物(奥利司他、芬特明-托吡酯、安非他酮-纳曲酮或司美拉诺肽)后原发性开角型青光眼(POAG)和高眼压的风险;倾向评分匹配后两组各61057例,GLP-1RA组在3年和5年随访时POAG和高眼压风险均显著较低。
要点
- GLP-1RA组3年POAG风险降低50.4%(RR 0.496,95%CI 0.371-0.664),5年降低58.5%(RR 0.415,95%CI 0.316-0.545)。
- GLP-1RA组3年高眼压风险降低55.9%(RR 0.441,95%CI 0.318-0.611),5年降低65.8%(RR 0.342,95%CI 0.250-0.466)。
- 结论:无糖尿病患者使用GLP-1RA相比替代减重治疗,3年和5年POAG及高眼压风险显著较低。
核心结论
- 在无糖尿病患者中,使用GLP-1RA相比替代减重治疗,3年和5年时POAG和高眼压风险显著较低。
研究设计与样本
- 回顾性队列研究,分析TriNetX研究网络2004年1月至2024年12月的国际电子健康记录数据。
- 研究对象为无糖尿病、诊断超重或肥胖并接受GLP-1RA或替代减重药物(奥利司他、芬特明-托吡酯、安非他酮-纳曲酮或司美拉诺肽)治疗的患者。
- 在3年和5年评估结局,采用倾向评分匹配(PSM)匹配基线人口学、合并症和用药,计算风险比(RR)及95%置信区间(CI)。
- 倾向评分匹配后两组各61057例患者。
主要发现
- GLP-1RA组3年POAG风险降低50.4%(RR 0.496,95%CI 0.371-0.664),5年降低58.5%(RR 0.415,95%CI 0.316-0.545)。
- GLP-1RA组3年高眼压风险降低55.9%(RR 0.441,95%CI 0.318-0.611),5年降低65.8%(RR 0.342,95%CI 0.250-0.466)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the risk of primary open-angle glaucoma (POAG) and ocular hypertension in patients with obesity taking glucagon-like peptide 1 receptor agonists (GLP-1RAs) versus alternative weight loss medications. DESIGN: A retrospective cohort study of the TriNetX research network was conducted by analyzing international electronic health record data from January 2004 through December 2024. PARTICIPANTS: Patients without diabetes who had a diagnosis of being overweight or obesity who were treated with either GLP-1RAs or alternative weight loss medications, including orlistat, phentermine-topiramate, bupropion-naltrexone, or setmelanotide. METHODS: Patients were assessed for outcomes at 3 and 5 years. Propensity score matching (PSM) was conducted between cohorts matched for baseline demographics, comorbidities, and medication use. Risk ratios (RR) and 95% confidence intervals (CIs) were calculated subsequently. MAIN OUTCOME MEASURES: Risk of POAG and ocular hypertension. RESULTS: After PSM, both cohorts comprised 61 057 patients. The risk of both POAG and ocular hypertension were significantly lower in the GLP-1RA group at both 3 and 5 years of follow-up. A 50.4% lower risk at 3 years (RR, 0.496; 95% CI, 0.371-0.664) and a 58.5% lower risk at 5 years (RR, 0.415; 95% CI, 0.316-0.545) for POAG developing was noted. Lower risks of 55.9% at 3 years (RR, 0.441; 95% CI, 0.318-0.611) and 65.8% at 5 years (RR, 0.342; 95% CI, 0.250-0.466) for ocular hypertension developing were noted. CONCLUSIONS: In patients without diabetes, the use of GLP-1RAs exhibited a significantly lower risk of POAG and ocular hypertension compared with alternative weight loss therapy at 3-year and 5-year intervals. FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
引用
- Vasu P, Dorairaj EA, Weinreb RN, et al. Risk of Glaucoma in Patients without Diabetes Using a Glucagon-Like Peptide 1 Receptor Agonist. Ophthalmology. 2025. PMID: 39978437. doi:10.1016/j.ophtha.2025.02.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。